Orca Security Offers Best-in-Class Approach to Secure Cloud-Native Applications, Expanding with ThreatOptix’s Agent-Based Runtime Protection
21.2.2023 14:00:00 EET | Business Wire | Press release
Orca Security, the pioneer of agentless cloud security, today announced that the Orca Cloud Security Platform will include ThreatOptix’s agent-based runtime protection and enforcement for cloud-native applications, including virtual machines, containers, and Kubernetes applications. While Orca remains committed to agentless cloud security, this new capability builds on Orca's industry leadership in delivering the most comprehensive coverage and visibility across the cloud estate and offers customers a choice in how they want to secure their applications.
New capabilities from ThreatOptix, whose technology provides comprehensive Linux security with an emphasis on cloud workload protection, will enhance the runtime detection and enforcement within the Orca Cloud Security Platform. The new features in the Orca Platform will be delivered via a strategic partnership with ThreatOptix, where all agent deployments and policy management, as well as data, will be fully integrated into the Orca Platform and sold as a single platform.
Security teams have many challenges in securing modern workloads, including vulnerability management, compliance monitoring, and advanced threat detection and prevention. Orca has been solely focused on delivering best-in-breed agentless capabilities to address these concerns. Yet there are specific mission critical applications where organizations may require an agent for advanced runtime protection and enforcement.
According to Enterprise Strategy Group*, “The growing footprint of Linux-based workloads, both virtual machine instances and application containers, has become a more prominent facet of the attack surface. Because these assets are temporal, they are often not running when security analysts are conducting investigations. As such, capturing system activity with an EDR offering that is purpose-built for Linux workloads is required.”
“At Orca Security, we have a mission to continually innovate cloud security and push the limits of what’s possible to be your key partner for securing the entirety of your cloud environments now and in the future,” said Avi Shua, CEO and co-founder of Orca Security. “As we expand our Cloud Security Platform, we are strategically partnering with ThreatOptix due to their core focus on delivering runtime protection and enforcement for cloud-native applications.”
ThreatOptix was founded by Ehud (“Udi”) Shamir and Sameet Mehta. Udi co-founded the XDR pioneer SentinelOne, where Sameet served as CFO, and both bring years of experience in workload runtime protection.
“At ThreatOptix, we have focused on cloud workload protection from inception,” said Udi Shamir. “The existing EDR solutions are not optimized to address the dynamic and ephemeral nature of modern cloud-native applications that run on containers and Kubernetes. Partnering with Orca, the leader in agentless cloud security, will strengthen an already innovative solution to better address the use cases for deploying an agent for cloud workload protection.”
Upon this integration, Orca Cloud Security Platform customers will be able to immediately deploy and manage the ThreatOptix agent as well as configure policies from the Orca UI. All agent-based runtime telemetry will be fully available within the Orca Unified Data Model to ensure ease-of-use and operation.
“Many partnerships in the cybersecurity ecosystem lack a deep integration strategy. This leads to duct-taped solutions that are inefficient and lack value for their users,” said Gil Geron CPO and co-founder of Orca Security. “We believe this strategic partnership and integration will be transformative for securing the cloud in a purpose-built way to deliver a seamless solution sold under a single SKU. Once integrated, Orca customers will have a seamless experience with the agent acting similarly to a native Orca capability. The Platform will support all cloud environments secured by us today, including highly regulated environments like FedRAMP.”
To learn more about how Orca is focused on securing cloud environments and addressing cloud risks, visit the Orca Blog. Additionally, organizations interested in trialing the Orca Platform can sign up for a free, 30-day cloud risk assessment.
Availability
The integrated solution will be available in the second half of 2023.
About Orca Security
Orca Security is the pioneer of agentless cloud security that is trusted by hundreds of enterprises globally. Orca makes cloud security possible for enterprises moving to and scaling in the cloud with its patented SideScanning™ technology and Unified Data Model. The Orca Cloud Security Platform delivers the world's most comprehensive coverage and visibility of all risks across the cloud. With this continuous first-to-market innovations and expertise, the Orca Cloud Security Platform ensures security teams quickly identify and remediate risks to keep their businesses secure. Connect your first account in minutes: https://orca.security or take the free cloud risk assessment.
About ThreatOptix
ThreatOptix provides peerless server protection architected from the ground-up to defend Linux, with a technology that makes it easy for large enterprises and government agencies to detect, classify and mitigate threats with greater efficacy than any existing offering.
* ESG: The Maturation of Cloud-native Security 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005278/en/
Contact information
Media
Emily Townsend
fama PR for Orca Security
orca@famapr.com
Kirtee Londhe Mehta
PR for ThreatOptix, Inc.
kirtee@threatoptix.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
